DCTH Delcath stock news
On September 14, 2026, during its corporate presentation at the H.C. Wainwright Global Investment Conference, Delcath Systems Inc. (Nasdaq: DCTH) management announced that the company is currently trending ahead of its third--quarter 2026 revenue guidance. This outperformance is attributed to increased patient volumes and improved reimbursement efficiency following the recent regulatory progress for the HEPZATO KIT. Management reaffirmed its strategic objective to have 30 active commercial treatment centers operational by December 31, 2026, and is scheduled to provide further updates at the H.C. Wainwright 27th Annual Global Investment Conference on September 15, 2026.